CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation
SAN DIEGO, March 2, 2023 /PRNewswire/ — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences has received preliminary approval a proposed settlement of a derivative lawsuit pending in Nevada. The lawsuit alleged breach of fiduciary duty and other claims premised on the same events that were the subject of a purported class action filed in the Southern District of New York on April 23, 2014. On July 2, 2019, the court entered a final order dismissing the class action complaint with prejudice.
Related news for (CVSI)
- CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
- CV Sciences, Inc. To Announce Second Quarter 2024 Results On August 13, 2024
- CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER
- CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results
- CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews